48. 原発性抗リン脂質抗体症候群 Primary antiphospholipid syndrome Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05078710 (ClinicalTrials.gov) | July 1, 2021 | 24/9/2021 | Telitacicept in Primary APS Patients | A Pilot Study of Telitacicept Treatment in Primary APS Patients | Anti Phospholipid Syndrome | Drug: Telitacicept | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | China |